Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization
Beta Drugs Ltd · Others (Uncategorized) · 22 Oct 2026, 11:07 pm
Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization Beta Drugs Limited confirmed nil deviation in utilizing funds from its ₹117.01 crore preferential issue (raised on 25th Nov'24) for the quarter ended 30th Sep'26. Against the allocated ₹117 crore, cumulative fund deployment reached ₹47.37 crore. Major deployments include ₹19.94 crore for capital investment/acquisitions (allocated ₹20 crore), ₹13.36 crore for general corporate purposes (allocated ₹15 crore), ₹9.52 crore for manufacturing capex (allocated ₹44 crore), and ₹3.60 crore for subsidiary facility upgrades. Brickwork Ratings India serves as the monitoring agency.
Original exchange filing (PDF)
More announcements from Beta Drugs Ltd
- BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Nov-2026 to consider Other business. · 16 Nov 2026
- To consider other business matters · 16 Nov 2026
- Monitoring Agency Report as on 30th September, 2026 · 12 Nov 2026
- Beta Drugs Limited has informed the Exchange about Transcript · 28 Oct 2026
- Beta Drugs Limited has informed the Exchange about Link of Recording · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Presentation · 22 Oct 2026
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Schedule of meet · 22 Oct 2026
